A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor
Pediatric Pulmonology · 2024
DOI: 10.1002/ppul.27273 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2024. Verfasst von Nora Burdis und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Lung Transplantation, Benzodioxoles, Referral and Consultation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIDDK NIH HHS, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Rationale
In 2015, a survey of cystic fibrosis (CF) physicians showed significant gaps in lung transplant (LTx) referral knowledge. Subsequently, LTx referral guidelines for people with CF were published, and elexacaftor/tezacaftor/ivacaftor (ETI) became available for >80% of people in the United States (US). We sought to assess physicians’ LTx referral knowledge and self‐reported referral practices.
Methods
CF center directors in the US were surveyed about LTx. Questions addressed transplant referral indications, contraindications, testing, and the impact of ETI on referral timing. Thematic analysis was used to assess responses to open‐ended questions.
Results
There were 110/309 (36%) responses. Respondents identified several referral indications, including rapid decline in FEV 1 (93%), recurrent hemoptysis (80%), hypoxemia (79%), and pulmonary hypertension (75%). Over 70% of respondents reported using oximetry, echocardiogram, and blood gas to assess disease severity. Respondents were more likely to find early LTx discussions useful for patients not on modulators versus on modulators (87% vs. 63%, p < .005). Most respondents (66%) reported delaying LTx referral for some patients with FEV 1 30%–40% who met criteria, while 26% had delayed referral for patients with FEV 1 < 30%. Uncertainty regarding optimal LTx referral timing for patients on ETI was a prominent theme of the qualitative analysis.
Conclusions
While physician knowledge about LTx referral indications appears improved since the CF referral guidelines were published, uncertainty about referral timing is pervasive, and the guidelines will need to be updated as more data become available about the long‐term effectiveness of ETI in advanced lung disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.
- Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
- Division of Pulmonary and Critical Care Medicine, University of California at Los Angeles, Los Angeles, California, USA.
- Division of Pulmonary and Critical Care Medicine, Columbia University, New York, New York, USA.
- Division of Pulmonary and Allergy, Department of Pediatrics, University of Washington, Seattle, Washington, USA.
- Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA.
ORCID-Profile: Nora Burdis
Förderung
- NIH HHS
- NIDDK NIH HHS
- Cystic Fibrosis Foundation
- NHLBI NIH HHS
- NINR NIH HHS
Zitieren
APA
Burdis, N., Milinic, T., Bartlett, L. E., Goss, L., Tallarico, E., Boyle, A., Thaxton, A., Turner, G. A., Benvenuto, L. J., Faro, A., Goss, C. H., Kapnadak, S. G., & Ramos, K. J. (2024). A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27273
Vancouver
Burdis N, Milinic T, Bartlett LE, Goss L, Tallarico E, Boyle A, et al. A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27273
BibTeX
@article{Burdis2024,
author = {Burdis, Nora and Milinic, Tijana and Bartlett, Lauren E and Goss, Louisa and Tallarico, Erin and Boyle, Abigail and Thaxton, Abigail and Turner, Grant A and Benvenuto, Luke J and Faro, Albert and Goss, Christopher H and Kapnadak, Siddhartha G and Ramos, Kathleen J},
title = {A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor},
journal = {Pediatric Pulmonology},
year = {2024},
doi = {10.1002/ppul.27273}
}
EUVIMED